NEW YORK and CAMBRIDGE, England, May 1, 2025 /PRNewswire/ -- Intima Bioscience, a clinical stage oncology company focused on curative intent in solid tumor cancers, presented data from a ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be effective for patients with metastatic colorectal cancer (CRC) refractory to ...

Dr. Lou is honored alongside Emma Weston-Dimery, his patient, underscoring Intima's impact on global health NEW YORK and CAMBRIDGE, England, Feb. 11, 2026 /PRNewswire/ -- Intima Bioscience, a clinical ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...

Immunotherapeutic strategies have made huge strides in cancer treatment for many solid tumors over the past decade. But the promising results have failed to make a large change in the treatment of ...

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

NEW YORK and CAMBRIDGE, England, Feb. 11, 2026 /PRNewswire/ -- Intima Bioscience, a clinical stage oncology company focused on curative intent in solid tumor cancer, today announced that Emil Lou, M.D ...